FDA Supac guidance for ER [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-09-09 16:04 (1730 d 23:23 ago) – Posting: # 19253
Views: 1,569

Hi John,

❝ To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?


Generally not. That’s a Level 3 Change.
See the guidance V. C. 2. b. Dissolution documentation:

In addition to application/compendial release requirements, a multipoint dissolution profile should be obtained using application/compendial test conditions for the changed drug product and the biobatch or marketed batch (unchanged drug product). Adequate sampling should be performed, for example at 1, 2, and 4 hours and every two hours thereafter until either 80% of the drug from the drug product is released or an asymptote is reached.

But don’t forget V. C. 2. c. Bioequivalence documentation:

A single-dose bioequivalence study. The bioequivalence study may be waived in the presence of an established in vitro/in vivo correlation.


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,618 posts in 4,741 threads, 1,611 registered users;
17 visitors (0 registered, 17 guests [including 7 identified bots]).
Forum time: 15:28 CEST (Europe/Vienna)

There are in fact two things, science and opinion;
the former begets knowledge, the latter ignorance.    Hippocrates

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5